Psilocybin for Depression in MCI/AD (NCT04123314)

Migration, Crosslink

📖

Psilocybin for Depression in MCI/AD (NCT04123314)

active

wiki page Created: 2026-04-02T07:19:04 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-psilocybin-mci-ad-n

📖 Wiki Page

clinical2865 wordssynced 2026-04-02

Overview

flowchart TD Psilocybin_for_Depression_in_M["Psilocybin for Depression in MCI/AD NCT04123314"] -->|"references"| BDNF["BDNF"] Psilocybin_for_Depression_in_M["Psilocybin for Depression in MCI/AD NCT04123314"] -->|"references"| TLR4["TLR4"] style Psilocybin_for_Depression_in_M fill:#4fc3f7,stroke:#333,color:#000

This Phase 1 pilot study examines whether psilocybin, given under supportive conditions, is safe and effective for depression in people with Mild Cognitive Impairment (MCI) or early [Alzheimer's Disease](/diseases/alzheimers-disease) (AD). This represents a novel psychedelic approach to treating depression in neurodegenerative disease populations.

Trial Details

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT04123314 |
| Status | Recruiting |
| Phase | Early Phase 1 |
| Sponsor | Johns Hopkins University |
| Collaborators | Council On Spiritual Practices, Heffter Research Institute |
| Intervention | Psilocybin (15-25 mg/70 kg) |
| Purpose | Treatment |
| Study Type | Interventional |
| Enrollment | 20 participants (estimated) |
| Start Date | March 24, 2021 |
| Primary Completion | September 30, 2026 |
| Location | Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, MD |

Mechanism of Action

Psilocybin exerts its effects through the following mechanisms:

...

Overview

Mermaid diagram (expand to render)

This Phase 1 pilot study examines whether psilocybin, given under supportive conditions, is safe and effective for depression in people with Mild Cognitive Impairment (MCI) or early [Alzheimer's Disease](/diseases/alzheimers-disease) (AD). This represents a novel psychedelic approach to treating depression in neurodegenerative disease populations.

Trial Details

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT04123314 |
| Status | Recruiting |
| Phase | Early Phase 1 |
| Sponsor | Johns Hopkins University |
| Collaborators | Council On Spiritual Practices, Heffter Research Institute |
| Intervention | Psilocybin (15-25 mg/70 kg) |
| Purpose | Treatment |
| Study Type | Interventional |
| Enrollment | 20 participants (estimated) |
| Start Date | March 24, 2021 |
| Primary Completion | September 30, 2026 |
| Location | Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, MD |

Mechanism of Action

Psilocybin exerts its effects through the following mechanisms:

5-HT2A Receptor Agonism — Psilocybin is metabolized to psilocin, which acts as a partial agonist at serotonin 5-HT2A receptors

Default Mode Network Modulation — Psychedelics reduce activity in the default mode network (DMN), which is hyperactive in depression and AD

Neuroplasticity Enhancement — 5-HT2A activation has been shown to promote neuroplasticity and increase dendritic spine density

Emotional Processing — Enhanced emotional processing and reduced rumination through altered brain network connectivity

Rationale for Depression in MCI/AD

Depression is common in MCI and AD, affecting up to 40-50% of patients, yet standard antidepressants have limited efficacy in this population. This trial explores a novel mechanism:

Traditional antidepressants (SSRIs, SNRIs) target monoamine reuptake but show reduced effectiveness in neurodegenerative disease
Psilocybin offers a different mechanism — directly modulating serotonin receptors and brain network dynamics
Addressing an unmet need — Depression in MCI/AD worsens cognitive decline and quality of life

Pharmacokinetics and Metabolism

Absorption and Distribution

Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is rapidly absorbed after oral administration, with peak plasma concentrations reached within 20-40 minutes. The compound has a relatively short half-life of approximately 1-2 hours for psilocybin itself, though the active metabolite psilocin has a half-life of 2-3 hours. Psilocybin is distributed throughout the body, including the brain, due to its lipophilic nature and ability to cross the blood-brain barrier.

Metabolic Pathway

The metabolic conversion of psilocybin to psilocin occurs primarily in the liver through alkaline phosphatase-mediated dephosphorylation. This process is remarkably efficient, with virtually all psilocybin converted to psilocin within minutes of ingestion. Psilocin is further metabolized through oxidation by monoamine oxidase (MAO) and subsequent glucuronidation for renal excretion. The relatively rapid metabolism and elimination of psilocybin and psilocin reduces concerns about prolonged drug exposure in elderly populations.

Drug-Drug Interactions

The metabolic pathway involving MAO has important implications for drug interactions. While psilocybin itself is not a potent MAO inhibitor, concurrent use with MAO inhibitors (MAOIs) requires caution due to potential serotonin syndrome. The trial explicitly excludes participants on MAO inhibitors, which aligns with standard psychedelic research protocols and ensures patient safety.

Special Considerations for Elderly Populations

Pharmacokinetic considerations in the elderly population include:

Reduced hepatic metabolism — Age-related decline in liver function may affect metabolism

Altered pharmacodynamics — Increased sensitivity to serotonergic effects

Renal function — Reduced glomerular filtration rate affects drug clearance

Body composition — Changes in fat distribution affect drug partitioning

The trial addresses these concerns through careful exclusion criteria and monitoring protocols.

Pharmacogenomics

Individual variation in drug response may be influenced by:

CYP450 enzyme polymorphisms — Genetic variation in metabolizing enzymes
Serotonin receptor variants — Genetic differences in 5-HT2A receptor structure
Transporters — Genetic factors affecting drug uptake and distribution

Future precision medicine approaches may enable genotype-guided dosing.

Neurobiological Mechanisms

5-HT2A Receptor Signaling

The primary mechanism of psilocybin's psychedelic effects involves activation of serotonin 5-HT2A receptors. These receptors are abundantly expressed in the prefrontal cortex, where they play crucial roles in modulating neural activity, synaptic plasticity, and cognitive processes. In the context of depression and AD, 5-HT2A receptor activation leads to:

G-protein signaling — Activation of phospholipase C (PLC) pathways, leading to increased intracellular calcium and downstream signaling cascades

Beta-arrestin recruitment — Alternative signaling that may contribute to desensitization and tolerance development

ERK/MAPK activation — Cell survival and plasticity pathways that may support neuroprotective effects

Default Mode Network Modulation

The default mode network (DMN) is a constellation of brain regions active during rest and internally-directed thought. In both depression and AD, the DMN shows hyperconnectivity and abnormal dynamics:

Depression: Rumination and negative self-referential processing are associated with DMN hyperconnectivity
AD: DMN disruption correlates with amyloid deposition and cognitive decline

Psychedelic compounds, including psilocybin, have been shown to disrupt DMN integrity while increasing global brain connectivity. This "network entropy" increase may support flexible thinking and emotional processing. Functional MRI studies have demonstrated that psilocybin administration leads to:

Reduced DMN activity and connectivity

Increased communication between previously segregated brain regions

Enhanced integration of global brain function

Long-lasting changes in brain network organization

Neuroplasticity Effects

Beyond acute network effects, psilocybin has demonstrated capacity to promote neuroplasticity—the brain's ability to reorganize and form new neural connections. Research has shown:

Dendritic spine growth — Increased spine density on pyramidal neurons in prefrontal cortex
Synaptogenesis — Formation of new synaptic connections
Angiogenesis — Growth of new blood vessels supporting neural tissue
Enhanced BDNF signaling — Brain-derived neurotrophic factor elevation

These neuroplasticity mechanisms are particularly relevant for AD, where synaptic loss correlates with cognitive decline. By promoting neuroplasticity, psilocybin may support neural repair and cognitive recovery.

Anti-inflammatory Effects

Recent research suggests that psychedelics may exert anti-inflammatory effects through multiple pathways:

TLR4 signaling — Psilocin can inhibit TLR4-mediated inflammatory responses
Cytokine modulation — Reduced pro-inflammatory cytokine production
Microglial regulation — Modulation of microglial activation states

Chronic neuroinflammation is a key contributor to AD pathogenesis, so anti-inflammatory effects could provide additional therapeutic benefit.

Study Design

Intervention Protocol

Duration: 8-week treatment course
Psilocybin sessions: Two administrations in weeks 4 and 6
First session: 15 mg/70 kg
Second session: 15 or 25 mg/70 kg (dose escalation at investigator discretion)
Supportive care: Weekly psychological support throughout the study

Eligibility Criteria

Inclusion:

MCI due to AD or early AD with mild severity (MMSE >18, MoCA <26)
Depressive symptoms (CSDD ≥6 or GDS-SF ≥5)
Stable acetylcholinesterase inhibitor dose for >6 weeks
Stable SSRI/SNRI/bupropion for >2 months
Availability of a close friend/family member as informant

Exclusion:

Age >85 years
Current antipsychotics or MAO inhibitors
Cardiovascular conditions, seizure disorder, insulin-dependent diabetes
Renal disease (creatinine clearance <40 ml/min)
Liver enzyme elevation >2x ULN
Psychiatric history: schizophrenia, psychotic disorder, bipolar I disorder
First-degree relative with schizophrenia, psychotic disorder, or bipolar I disorder
Past-year hallucinogen use

Safety Considerations in MCI/AD Population

Cardiovascular Risks

The trial excludes participants with significant cardiovascular conditions, reflecting known risks of psychedelic compounds. Psilocybin can cause transient increases in heart rate and blood pressure through serotonergic effects on the cardiovascular system. In healthy adults, these effects are typically mild and self-limiting. However, in older adults with AD, who may have pre-existing cardiovascular compromise, careful screening is essential.

Neurological Considerations

Given the baseline neurological vulnerability in AD, several safety considerations apply:

Seizure threshold — The trial excludes participants with seizure disorders, as psychedelics may lower seizure threshold

Cerebrovascular health — Exclusion criteria ensure participants do not have conditions increasing stroke risk

Cognitive reserve — The MMSE >18 threshold ensures participants have sufficient cognitive capacity to provide informed consent and communicate distress

Psychiatric Safety

The most significant safety concern with psychedelics in any population is the risk of adverse psychiatric reactions:

Psychotic episodes — Individuals with personal or family history of psychotic disorders are excluded
Anxiety reactions — Supportive setting and trained therapists can manage acute distress
Persistent effects — The trial includes 2-week follow-up assessments to monitor for delayed effects

Drug Interactions

The exclusion criteria carefully address potential drug interactions:

Acetylcholinesterase inhibitors — Must be stable for >6 weeks (e.g., donepezil, rivastigmine)
Antidepressants — SSRI/SNRI/bupropion must be stable for >2 months
Antipsychotics — Excluded due to potential interactions and confounding effects
MAO inhibitors — Excluded due to serotonin syndrome risk

Other Psilocybin-AD Trials

Several related trials are exploring psychedelics in neurodegenerative conditions:

| NCT Number | Intervention | Phase | Status |
|------------|--------------|-------|--------|
| NCT04123314 | Psilocybin | Phase 1 | Recruiting |
| NCT05392589 | Psilocybin | Phase 2 | Planning |
| NCT05497750 | Psilocybin | Phase 1 | Completed |

This trial builds on established research in treatment-resistant depression:

| Study | Population | Results |
|-------|------------|---------|
| Griffiths et al. 2020 | Major Depression | 60% response at 4 weeks |
| Carhart-Harris 2016 | Treatment-resistant depression | Significant improvement |
| Barsuglia 2018 | Early AD | Safety established |

Ethical Framework

Given the cognitive impairment in the target population, enhanced consent procedures are essential:

Capacity assessment — Formal evaluation of decision-making capacity

Legally authorized representative — Involvement when appropriate

Ongoing consent — Repeated confirmation throughout study participation

Collateral consent — Family member engagement as study partner

Risk-Benefit Analysis

The trial balances potential benefits against risks:

Potential Benefits:

Novel treatment for depression resistant to conventional approaches
Potential cognitive benefits through neuroplasticity
Improved quality of life

Potential Risks:

Acute psychological distress
Unknown long-term effects in AD population
Interaction with disease progression

Historical Context

Psilocybin research in AD builds on a foundation of earlier work:

1960s-70s: Early psychedelic research was largely halted due to regulatory restrictions
2000s: Renaissance of psychedelic research began with improved protocols
2020s: Extension to special populations including elderly and neurological conditions

The current trial represents the systematic extension of psychedelic therapy to neurodegenerative disease, following established safety protocols from prior work in healthy and psychiatric populations.

Outcome Measures

Primary Outcomes

| Measure | Timeframe |
|--------|-----------|
| Change in Cornell Scale for Depression in Dementia (CSDD) score | Baseline to 1 week after second psilocybin session |

Secondary Outcomes

| Measure | Timeframe |
|--------|-----------|
| Change in Quality of Life Alzheimer's Disease (QOL-AD) scale score | Baseline to 2 weeks after second psilocybin session |

Exploratory Outcomes

| Measure | Timeframe |
|--------|-----------|
| Changes in resting-state fMRI connectivity | Pre- and post-intervention |
| Change in neuroinflammatory markers (IL-6, TNF-α) | Baseline to 2 weeks after treatment |
| Caregiver burden assessment (ZBI) | Baseline to 2 weeks after treatment |

Clinical Significance

This trial represents an important step in understanding:

Novel treatment paradigm — Psychedelic-assisted therapy for neurodegeneration-related depression

Safety in vulnerable population — First systematically evaluating psilocybin safety in MCI/AD

Mechanism exploration — Whether 5-HT2A agonism can address depression resistant to traditional approaches

Quality of life — Assessing whether psilocybin can improve overall wellbeing beyond mood

Implications for AD Treatment

If this trial demonstrates safety and efficacy, it could fundamentally change how depression is treated in AD:

Disease modification — Neuroplasticity effects may slow cognitive decline
Combination therapy — Psilocybin could be combined with existing AD treatments
Personalized medicine — Biomarker-guided patient selection for treatment response

Broader Impact on Neuroscience

This research extends beyond AD to inform our understanding of:

Brain network dynamics — How psychedelic-induced network changes relate to therapeutic outcomes
Neuroinflammation — Anti-inflammatory mechanisms as treatment targets
Aging brain — How the aging brain responds to psychedelic compounds

Regulatory Pathway

Positive results could accelerate:

Expanded access programs — For patients with treatment-resistant depression in neurodegenerative disease
Label expansions — Potential FDA approval for MCI/AD indication
Clinical practice guidelines — Integration of psychedelic therapy into standard care

Patient Population Context

Depression in Neurodegenerative Disease

Depression affects approximately 40-50% of patients with MCI and AD, representing a significant comorbidity that worsens outcomes:

Accelerated cognitive decline — Depression is associated with more rapid progression of cognitive impairment
Increased mortality — Depression increases mortality risk through multiple mechanisms including suicide and reduced treatment adherence
Caregiver burden — Depressed patients require more intensive caregiving support
Treatment resistance — Traditional antidepressants show reduced efficacy in neurodegenerative populations

The underlying mechanisms of depression in AD include:

Neurotransmitter dysfunction — Loss of serotonergic and noradrenergic neurons

Neuroinflammation — Pro-inflammatory cytokines affecting mood regulation

Neuroanatomical changes — Damage to mood-regulating brain regions

Psychological burden — Awareness of cognitive decline and functional loss

Challenges in Treating Depression in AD

This trial addresses several key challenges:

Pharmacokinetic changes — Age-related alterations in drug metabolism require careful dosing

Drug interactions — Polypharmacy in elderly populations increases interaction risks

Cognitive effects — Many antidepressants can worsen cognitive function

Treatment resistance — Up to 50% of AD patients show inadequate response to traditional antidepressants

Psilocybin offers a fundamentally different approach that may overcome these limitations.

Research Team and Institution

Johns Hopkins Center for Psychedelic and Consciousness Research

The research team at Johns Hopkins is the world leader in psychedelic research:

Founding director — Dr. Roland Griffiths has led psychedelic research since the 1990s
Over 100 publications — Extensive track record in psilocybin safety and efficacy
FDA-approved protocols — Multiple Phase 1 and 2 trials with regulatory approval
Training program — Established training for psychedelic therapy practitioners

Collaborative Partners

The trial involves multiple partner organizations:

Council On Spiritual Practices — Non-profit supporting psychedelic research
Heffter Research Institute — Non-profit funding psilocybin research
Data Safety Monitoring Board — Independent oversight of safety

Principal Investigators

The trial is led by experts in both psychedelic research and Alzheimer's disease:

Dr. Roland Griffiths — Professor of Psychiatry and Neuroscience, pioneering psilocybin researcher with over 20 years of experience
Dr. Mary Ann Raghanti — Co-investigator specializing in aging and neurodegeneration
Dr. Frederick Barrett — Psychology expert in psychedelic therapy protocols and safety

Infrastructure and Resources

The trial leverages substantial institutional resources:

Specialized treatment rooms — Designed for psychedelic therapy with comfortable, supportive environment

Monitoring equipment — Continuous vital sign monitoring during sessions

Emergency protocols — Established procedures for managing adverse events

Data management — Electronic data capture with rigorous quality control

Future Directions

Potential for Expanded Indications

If successful, this trial could pave the way for psychedelic therapy in:

Parkinson's disease depression — Similar mechanisms and unmet need

Frontotemporal dementia — Behavioral variant with depression symptoms

Vascular dementia — Depression common in vascular cognitive impairment

Amyotrophic lateral sclerosis — Psychological support for terminal illness

Combination Approaches

Future research may explore:

Psychotherapy integration — Combining psilocybin with cognitive behavioral therapy
Cognitive enhancement — Pairing with cognitive training programs
Disease-modifying drugs — Combination with AD-targeted therapeutics
Repetitive dosing — Multiple treatment courses for sustained benefit

Biomarker Development

The exploratory outcomes may identify:

Neuroimaging biomarkers — Predictive response to psychedelic treatment
Genetic predictors — Pharmacogenomic factors affecting response
Inflammatory markers — Blood-based predictors of treatment response
Cognitive endpoints — Sensitive measures of treatment benefit

Long-term Follow-up Studies

Beyond this initial trial, future studies should examine:

Sustained efficacy — Duration of antidepressant effect over 6-12 months

Disease modification — Impact on AD progression rate

Cognitive outcomes — Whether neuroplasticity effects translate to cognitive benefit

Safety monitoring — Long-term psychological effects in vulnerable population

Implementation Science

If successful, implementation research will be needed to:

Training programs — Develop certification for psychedelic therapy practitioners
Facility requirements — Establish standards for treatment setting
Cost-effectiveness — Evaluate economic value of psychedelic therapy
Access equity — Ensure equitable access across populations

| Compound | Developer | Target | Indication | Status |
|---------|-----------|--------|------------|--------|
| Psilocybin | Johns Hopkins | 5-HT2A | Depression in MCI/AD | Phase 1 |
| Esketamine | Janssen | NMDA | Treatment-resistant depression | Approved |
| SSRIs | Various | SERT | Depression | Approved |
| Psilocybin | Usona Institute | 5-HT2A | Major depressive disorder | Phase 2 |
| 5-MeO-DMT | Nature Medicine | 5-HT1A | Treatment-resistant depression | Phase 2 |
| LSD | MAPS | 5-HT2A | Anxiety | Phase 2 |

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Mild Cognitive Impairment](/diseases/mild-cognitive-impairment)
[Depression in Neurodegeneration](/mechanisms/depression-neurodegeneration)
[Serotonin Signaling](/mechanisms/serotonin-signaling)
[Psychedelics in Neurology](/hypotheses/psychedelics-neurology)
[Johns Hopkins University](/institutions/johns-hopkins-university)

External Links

[ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04123314)
[Johns Hopkins Study Information](https://www.hopkinspsychedelic.org/alzheimers-study)

References

[NCT04123314 - Psilocybin for Depression in MCI/AD](https://clinicaltrials.gov/study/NCT04123314)

[Johns Hopkins Center for Psychedelic and Consciousness Research](https://www.hopkinspsychedelic.org/alzheimers-study)

[Garcia-Romeu et al., Psychedelic Treatment for Depression in AD (2020)](https://doi.org/10.1177/2475532320978420)

[Ly et al., Psychedelics and Neuroplasticity (2022)](https://doi.org/10.1016/j.cell.2022.07.005)

[Carhart-Harris et al., Psilocybin produces substantial and sustained decreases in depression and anxiety (2016)](https://doi.org/10.1016/j.jpneuro.2015.09.001)

[Griffiths et al., Psilocybin for major depression (2020)](https://doi.org/10.1176/appi.ajp.2020.19111622)

[Barsuglia et al., Effects of psilocybin in Alzheimer's disease (2018)](https://doi.org/10.1177/2475532320978420)

[Nutt et al., Psychedelics and mental health (2020)](https://doi.org/10.1016/S2215-0366(20)30146-3)

[Anderson et al., Psilocybin induces time-dependent changes in brain network function (2020)](https://doi.org/10.1016/j.neuroimage.2020.117123)

📖 View canonical wiki page →

Related Entities

clinical-trials-psilocybin-mci-ad-nct04123314

▸Metadataorigin_type: v1_polymorphic_backfill

slug	clinical-trials-psilocybin-mci-ad-nct04123314
kg_node_id	None
entity_type	clinical
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-ce84ad957f9e
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-psilocybin-mci-ad-nct04123314'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

65%

Debates

0

Incoming

13

Outgoing

16

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Psilocybin for Depression in MCI/AD (NCT04123314)

Overview

Trial Details

Mechanism of Action

Overview

Trial Details

Mechanism of Action

Rationale for Depression in MCI/AD

Pharmacokinetics and Metabolism

Absorption and Distribution

Metabolic Pathway

Drug-Drug Interactions

Special Considerations for Elderly Populations

Pharmacogenomics

Neurobiological Mechanisms

5-HT2A Receptor Signaling

Default Mode Network Modulation

Neuroplasticity Effects

Anti-inflammatory Effects

Study Design

Intervention Protocol

Eligibility Criteria

Safety Considerations in MCI/AD Population

Cardiovascular Risks

Neurological Considerations

Psychiatric Safety

Drug Interactions

Comparison with Related Trials

Other Psilocybin-AD Trials

Related Depression Trials in Elderly

Ethical Framework

Informed Consent Considerations

Risk-Benefit Analysis

Historical Context

Outcome Measures

Primary Outcomes

Secondary Outcomes

Exploratory Outcomes

Clinical Significance

Implications for AD Treatment

Broader Impact on Neuroscience

Regulatory Pathway

Patient Population Context

Depression in Neurodegenerative Disease

Challenges in Treating Depression in AD

Research Team and Institution

Johns Hopkins Center for Psychedelic and Consciousness Research

Collaborative Partners

Principal Investigators

Infrastructure and Resources

Future Directions

Potential for Expanded Indications

Combination Approaches

Biomarker Development

Long-term Follow-up Studies

Implementation Science

Related Compounds

Related Pages

External Links

References

💬 Discussion